| 1 |
31253572 | IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. | 2019 Aug |
2 |
| 2 |
30001170 | IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. | 2018 Aug |
1 |
| 3 |
28400633 | New Targeted Treatments for Cutaneous T-cell Lymphomas. | 2017 Mar-Apr |
2 |
| 4 |
28912774 | Therapeutic Antibodies to KIR3DL2 and Other Target Antigens on Cutaneous T-Cell Lymphomas. | 2017 |
1 |
| 5 |
27037558 | KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma. | 2016 Aug |
4 |
| 6 |
26405593 | A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies. | 2015 Sep |
1 |
| 7 |
25361998 | IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. | 2014 Nov 1 |
2 |